Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 986-993

  Hill, Brian T ^a,b   Rybicki, Lisa ^b   Smith, Stephen ^a   Dean, Robert ^a   Kalaycio, Matt ^a   Pohlman, Brad ^a   Sweetenham, John ^a   Tench, Shawnda ^b   Sobecks, Ronald ^a   Andresen, Steven ^a   Copelan, Edward ^a   Bolwell, Brian J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

autologous stem cell transplant; hyper CVAD; Mantle cell lymphoma; mobilization

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IFOSFAMIDE; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LYMPHOMA, MANTLE-CELL; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 79957510429     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.551154     Document Type: Article

References (25)

1. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005;17:425-431. (Pubitemid 41226481)
2. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793-800. (Pubitemid 36315101)
3. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression- free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
4. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-593. (Pubitemid 34449738)
5. Jacobsen E, Freedman A. An update on the role of highdose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004;16:106-113. (Pubitemid 38402521)
6. Magni M, Di Nicola M, Carlo-Stella C, et al. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009;43: 509-511.
7. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-6414. (Pubitemid 46222241)
8. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
9. Dreyling MH, Hoster E, Van Hoof A, et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial of the European MCL Network. Blood 2008;112 (Suppl 1):Abstract 769.
10. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
11. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheralblood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995;13:1328-1335.
12. Gunn N, Damon L, Varosy P, et al. High CD34cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2003;9:643-648. (Pubitemid 38351783)
13. Weaver CH, Hazelton B, Rirch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
14. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-831. (Pubitemid 24264657)
15. DArena G, Musto P, Di Mauro L, et al. Predictive parameters for mobilized peripheral blood CD34progenitor cell collection in patients with hematological malignancies. Am J Hematol 1998;58:255-262. (Pubitemid 28346009)
16. de la Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002;42:4-9.
17. Drake M, Ranaghan L, Morris TC, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997;98:745-749. (Pubitemid 27386559)
18. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794. (Pubitemid 24175570)
19. Tarella C, Zallio F, Caracciolo D, et al. Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999;17:55-61. (Pubitemid 29063690)
20. Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, et al. The hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol 2006;Sep;24(3):159-63. (Pubitemid 44483910)
21. Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-hodgkin lymphoma with busul- fan, cyclophosphamide and etoposide. Br J Haematol 2010; Jan;148(2):226-34.
22. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994;Dec;14(6):913-8.
23. Ho J, Yang L, Banihashemi B, Martin L, Halpenny A, Atkins H, et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-hodgkins lymphoma. Bone Marrow Transplant 2009;Feb;43(3): 223-8.
24. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P, et al. Outcome of high-dose therapy and autologous transplantation in non-hodgkins lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 19.
25. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non- Hodgkins lymphoma. J. Clin Oncol 2009;Oct 1;27(28): 4767-73.